I very nearly never look at institutional ownership and have only a superficial appreciation of technical analysis (though I appreciate the information shared here on support levels to help temper my disappointment).

I try to stay in my lane, as I am able to read and appreciate medical developments and the science behind it. I'm grumbling like the rest here are Regeneron receives accolades, public attention and federal money. No doubt, Cytodyn is the forgotten funny looking kid who eventually will save the day.

Most of us have exhausted reasonably available funds. No doubt my wife will not let me remortgage the house. Sorry to add more hot air to a rehashed discussion, but I really don't see what more can be done except hurry up and wait.

Tick ...... tock......